Detalhe da pesquisa
1.
ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
Am Heart J
; 164(5): 654-63, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23137495
2.
Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.
Circulation
; 122(22): 2301-12, 2010 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-21098436
3.
Four-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial.
Catheter Cardiovasc Interv
; 77(7): 1012-7, 2011 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20824770
4.
A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods.
Lancet
; 373(9667): 897-910, 2009 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-19286089
5.
An everolimus-eluting stent versus a paclitaxel-eluting stent in small vessel coronary artery disease: a pooled analysis from the SPIRIT II and SPIRIT III trials.
Catheter Cardiovasc Interv
; 76(1): 60-6, 2010 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20578194
6.
Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.
Catheter Cardiovasc Interv
; 75(7): 997-1003, 2010 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20517959
7.
Efficacy of everolimus eluting stent implantation in patients with calcified coronary culprit lesions: two-year angiographic and three-year clinical results from the SPIRIT II study.
Catheter Cardiovasc Interv
; 76(5): 634-42, 2010 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20690152
8.
Systemic exposure of everolimus after stent implantation: a pharmacokinetic study.
Am Heart J
; 156(4): 751.e1-7, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18926156
9.
Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent.
JACC Cardiovasc Interv
; 8(8): 1053-1063, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26205444
10.
Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial.
EuroIntervention
; 8(9): 1047-51, 2013 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-23339811
11.
The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials.
EuroIntervention
; 9(6): 709-20, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23628499
12.
Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial.
Heart
; 99(2): 98-105, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23118346
13.
Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial.
EuroIntervention
; 7(9): 1060-1, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21959320
14.
Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque?
Atherosclerosis
; 221(1): 106-12, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22209268
15.
Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial.
JACC Cardiovasc Interv
; 5(6): 656-65, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22721662
16.
Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold.
Int J Cardiovasc Imaging
; 27(6): 859-66, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20941544
17.
Serial in vivo intravascular ultrasound-based echogenicity changes of everolimus-eluting bioresorbable vascular scaffold during the first 12 months after implantation insights from the ABSORB B trial.
JACC Cardiovasc Interv
; 4(12): 1281-9, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22192369
18.
A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis.
EuroIntervention
; 5(7): 788-94, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20142192
19.
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
JACC Cardiovasc Interv
; 3(12): 1220-8, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21232715
20.
Monitoring in vivo absorption of a drug-eluting bioabsorbable stent with intravascular ultrasound-derived parameters a feasibility study.
JACC Cardiovasc Interv
; 3(4): 449-56, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20398874